Down 53% in 3 months while the S&P 500 fell 2%.
−3Long-term trend
SNDX's Quality Score rose 1 point on Tue, Nov 10, to -1. Its high and its low were both higher than the day before.
Follow SNDX's trial news. Pro members can get an alert when Syndax Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2023 high | Down 67% |
| Latest filing | 8-K, Nov 2 |
Tue Nov 3Syndax Announces CFO Transition
1 more big story on SNDX in the past 12 months, for Pro members.
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
Expected to report Thu Feb 25, after the close
4 more dates ahead: conferences, for Pro members.
About 12 quarters
Director Dennis Podlesak sold 8,000 shares on Oct 29, under a planned sale. 8 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
SNDX is #160 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 160 |
Expected to report Thu Feb 25, after the close (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $83.3M, 82% more than a year ago.
“Revuforj net revenue grew to $61 million, driven by a 20% increase in new patients and an increasing number of patients on therapy in the post-transplant setting.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $60.7M | $54.7M | $32M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 2)
| Measure | Figure |
|---|---|
| Total research and development plus selling, general and administrative expenses | about $400M |
“Syndax expects that its cash, cash equivalents and short- and long-term investments, combined with its anticipated product revenue, collaboration revenue and interest income, will enable the Company to reach profitability.”
From its results filing (SEC filing · Nov 2)
Its share count grew 16% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 2, 2026 | -0.1% | +9.1% | -27.1% |
| Aug 4, 2026 | -9.3% | +4.4% | +6.3% |
| Apr 30, 2026 | -2.8% | -10.8% | -4.2% |
Sales grew in three of the last seven years, to $172M in 2025. It made a profit in one of the eight years.
RSI 25.8, MACD below signal, below both averages. Not scored.
2 insiders sold $152K across 2 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: SNDX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
SNDX scores -1 today, which Breakaway calls Poor. It is #160 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 53% in 3 months while the S&P 500 fell 2%. Cash lasts about 12 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
SNDX scores -1 today, which Breakaway calls Poor (below zero). That is #160 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SNDX's -1.
2 insiders sold $152K across 2 filings in the last 6 months. No open-market buys on record. The newest is Michael A. Metzger, Chief Executive Officer, who sold $130K on Jun 1. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.